Permanent 100% Antimicrobial Medical Plastic

Information

  • Research Project
  • 8326570
  • ApplicationId
    8326570
  • Core Project Number
    R44NR011117
  • Full Project Number
    5R44NR011117-03
  • Serial Number
    011117
  • FOA Number
    PA-10-050
  • Sub Project Id
  • Project Start Date
    9/29/2008 - 17 years ago
  • Project End Date
    7/31/2014 - 11 years ago
  • Program Officer Name
    COTTON, PAUL
  • Budget Start Date
    8/1/2012 - 13 years ago
  • Budget End Date
    7/31/2014 - 11 years ago
  • Fiscal Year
    2012
  • Support Year
    03
  • Suffix
  • Award Notice Date
    7/12/2012 - 13 years ago

Permanent 100% Antimicrobial Medical Plastic

DESCRIPTION (provided by applicant): PERMANENT 100% ANTIMICROBIAL MEDICAL PLASTIC Combating infections is one of the major goals of the entire medical community due to the exponential cost associated with care of an infected patient. Technology innovations to reduce infection brought about by cross-contamination of patients staying in healthcare facilities can have major impact to the medical community in terms of both dollars and human lives. Approximately 5% to 10% of all patients entering a hospital will contact some form of infection during their stay at the healthcare facility. It is estimated that hospitals spend over $30 billion annually and over 100,000 lives can be lost as a result of nosocomial infections. Statistics show that personal hygiene consisting mainly of hand washing with antimicrobial soaps does not occur frequently enough to prevent the $30 billion dollar expenditure that healthcare facilities endure on an annual basis. Unfortunately, medical products containing only 0.1-1.0% of leachable antimicrobial additives only provide temporary antimicrobial action because the biocidal agent can be easily removed by washing or wiping the surface of the medical product. Brighton Development has developed with NIH support a 100% permanent antimicrobial plastic that can be used in numerous medical products found in the healthcare community. In Phase II, we would like to focus on exploiting the feasibility of this discovery as a permanent 100% antimicrobial material and demonstrate its advantages in combating infection in the healthcare environment. Brighton Development will generate the required data to obtain registration of the 100% antimicrobial products with the EPA and subsequently provide these products to the healthcare community. The goals of this project are in alignment with one of NIH top priorities of HAI elimination (Healthcare-associated Infections) that has dramatic impact in terms of both dollars and human lives.

IC Name
NATIONAL INSTITUTE OF NURSING RESEARCH
  • Activity
    R44
  • Administering IC
    NR
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    511257
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    361
  • Ed Inst. Type
  • Funding ICs
    NINR:511257\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BRIGHTON DEVELOPMENT, LLC
  • Organization Department
  • Organization DUNS
    118349872
  • Organization City
    CARY
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    275134010
  • Organization District
    UNITED STATES